A detailed history of Black Rock Inc. transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 4,120,508 shares of TERN stock, worth $23.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,120,508
Previous 3,315,529 24.28%
Holding current value
$23.9 Million
Previous $21.7 Million 29.02%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$4.54 - $8.2 $3.65 Million - $6.6 Million
804,979 Added 24.28%
4,120,508 $28.1 Million
Q1 2024

May 10, 2024

SELL
$4.86 - $8.19 $454,162 - $765,347
-93,449 Reduced 2.74%
3,315,529 $21.7 Million
Q4 2023

Feb 13, 2024

BUY
$3.37 - $6.86 $822,829 - $1.67 Million
244,163 Added 7.71%
3,408,978 $22.1 Million
Q3 2023

Nov 13, 2023

BUY
$4.7 - $8.55 $123,544 - $224,745
26,286 Added 0.84%
3,164,815 $15.9 Million
Q2 2023

Aug 11, 2023

BUY
$7.35 - $13.29 $17.9 Million - $32.4 Million
2,437,862 Added 347.93%
3,138,529 $27.5 Million
Q1 2023

May 12, 2023

BUY
$7.91 - $12.0 $3.17 Million - $4.81 Million
401,229 Added 133.99%
700,667 $8.3 Million
Q4 2022

Feb 13, 2023

BUY
$4.62 - $10.18 $60,729 - $133,816
13,145 Added 4.59%
299,438 $3.05 Million
Q3 2022

Nov 14, 2022

BUY
$1.87 - $6.42 $255,750 - $878,031
136,765 Added 91.46%
286,293 $1.69 Million
Q2 2022

Aug 12, 2022

SELL
$1.5 - $3.0 $881,119 - $1.76 Million
-587,413 Reduced 79.71%
149,528 $371,000
Q1 2022

May 12, 2022

SELL
$2.83 - $6.7 $24,321 - $57,579
-8,594 Reduced 1.15%
736,941 $2.19 Million
Q4 2021

Feb 10, 2022

BUY
$5.65 - $10.73 $807,831 - $1.53 Million
142,979 Added 23.73%
745,535 $5.27 Million
Q3 2021

Nov 09, 2021

BUY
$7.22 - $13.46 $1.19 Million - $2.22 Million
164,952 Added 37.69%
602,556 $6.28 Million
Q2 2021

Aug 11, 2021

BUY
$12.26 - $22.0 $5.37 Million - $9.63 Million
437,604 New
437,604 $5.37 Million

Others Institutions Holding TERN

About Terns Pharmaceuticals, Inc.


  • Ticker TERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,613,800
  • Market Cap $218M
  • Description
  • Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...
More about TERN
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.